Renalytix AI (GB:RENX) has released an update.
Renalytix AI, an AI-enabled diagnostics firm, has released its audited US GAAP financial results for the fiscal year ending June 30, 2024. Despite the groundbreaking FDA authorization of its kidneyintelX.dkd test for early-stage CKD risk assessment, the company has reported a net loss, with a decrease in total assets and an increase in total liabilities compared to the previous year.
For further insights into GB:RENX stock, check out TipRanks’ Stock Analysis page.
